Tackling ADC development
DDW Editor Reece Armstrong speaks to Francisca Neethling, Head of Biotherapeutic Services and Olivier Mirguet, Global Head of Chemistry, at Eurofins Discovery about the challenges of antibody drug conjugate drug discovery and development and how strategies have evolved over time for these important therapies.
RA: What are some common challenges developers are facing with ADC development?
FN & OM: Linker stability, achieving consistent drug-to-antibody ratio (DAR) and manufacturability of these complex molecules are some of the biggest challenges faced by ADC drug developers. It is essential that linkers are designed to ensure stability because premature payload release could result in off-target toxicity. Balancing efficacy with safety remains a challenge as payloads are often highly cytotoxic.
It is vital that once an optimal DAR has been determined, this ratio stays consistent through the lifetime of manufacturing so that lot-to-lot consistency is achievable, pharmacokinetics are predictable in patients, and unexpected toxicity does not occur.
Manufacturing complexity can also pose a challenge as ADCs require precise conjugation and characterisation and need to be scalable; often, dedicated containment labs are required to handle highly cytotoxic payloads.
RA: How have ADC development strategies evolved since the first approved ADC in 2000?
FN & OM: There have been significant advancements in linker technologies, leading to enhanced stability and a more controlled release upon reaching the target. We can now also regulate the length of the linker-payload (drug-linker-conjugate) so steric hindrance challenges can be solved. With better chemistry comes better stability and delivery.
Better target selection through multiple approaches has reduced off target effects and the advancements in both payload and antibody design have improved efficacy. Recently, developers have begun to explore bispecific antibody approaches in an effort to overcome resistance mechanisms.
RA: What are some technologies that are helping with the development of ADCs?
FN & OM: Artificial intelligence (AI) and machine mearning have shown great promise, especially in regard to improved antibody engineering and payload optimisation, leading to accelerated development. There have also been notable advancements in conjugation platforms, analytical tools, lab instrumentation with higher throughput, more physiologically relevant in vitro cell based assays and in vivo models for better ADC characterisation and efficacy profiles. Analytic software also continues to evolve, all leading towards a more complete and accurate (predictive) data package in preparation for regulatory filing. In many ways, all of these tools once thought of as somewhat inaccessible and cost prohibitive are now more common and ubiquitous.
RA: What advice can you offer to companies who might be early in the development of an ADC?
FN & OM: Invest in thorough target validation and engage early with CROs or other experts who have specialities in both chemistry and biology to build a strong rationale to take the programme forward.
Start with multiple, fully characterised payloads and antibodies with toxicity and immunogenicity assessments complete. It is extremely risky to start the construction/design of an ADC molecule with just one antibody as the drug-linker-conjugate could significantly and irreversibly change the molecule, affecting binding, stability and function. Ideally, matrix-type experiments should be performed utilising multiple linker designs so that a lead candidate (or a small set of candidates) is identified and more thorough characterisation and testing can move forward. Options, options, options!
It is also strongly advised to plan scalability from the start, working closely with CMC resources and engage early and often with regulatory agencies to align on expectations for safety and bioanalytical data.
RA: What does the future of the ADC market look like?
FN & OM: The market is expected to show significant growth in the coming years and somebody with an imagination is going to come up with the next blockbuster drug. Most of the “easy” targets are gone so the market will require creativity in both payload and antibody design and indication. For example, autoimmune, inflammatory and infectious diseases are all emerging areas of focus. Some of these therapeutic areas or targets once considered un-druggable by ADCs deserve a second look. Was a molecule set aside or abandoned many years ago because of underwhelming efficacy or because it was unable to effectively reach (access/bind) its target? An emerging strategy is to reinvest in some of these shelved molecules using the advancements in ADC development to drive new programmes. Furthermore, VHHs, Fabs and other binders may also be used in these drug conjugates; it is no longer exclusively antibodies.
The market continues to show an increase in strategic partnerships between pharmaceutical companies and biotech firms and/or academic labs in an effort to more quickly bring these novel therapies to an underserved patient population by sharing resources and expertise.
RA: Can computational methods assist with developing better optimised ADCs?
Absolutely! The increasing use of AI in drug discovery is certainly helpful in analysing existing datasets to identify novel targets, predicting antibody-antigen interactions and aiding in optimising antibody engineering to increase the number of potential drug-linker complex binding sites, optimising linker design for better stability, modelling pharmacokinetics etc. These computational methods can also aid in data analysis, accelerating the ADC development process.
However, regulatory agencies will still require the in-depth characterisation required for all ADCs, including but not limited to toxicity and efficacy, in vitro and potentially, in vivo.
RA: What are some of the unique testing services available to help with the development of ADCs?
FN & OM: First and foremost, safety of the entire molecule must be assessed to ensure that no off-target binding or any unexpected, unwanted effect of the conjugated modality occurs. While the safety profile would be known of the payload and antibody separately, confirmation is needed that the conjugation of the two has not resulted in a new drug with altered characteristics. Immunogenicity and effector function testing are also essential. Multiple services can be employed from SPR to Flow to ELISA for binding and cell-based assays to confirm efficacy and internalisation to generate a comprehensive data package.
DAR analysis is another assessment that needs to be performed, most commonly done through mass spectrometry as well as PK/PD profiling and stability and forced degradation studies.
RA: How important is a strong regulatory strategy for ADC developers?
FN & OM: A strong regulatory strategy is extremely important and results in a smooth IND and/or BLA submission. As mentioned earlier in the discussion, early and continuous engagement with regulatory agencies clarifies expectations, helps to navigate challenges as they arise and allows for superior clinical trial design. ADCs are complex biologics and this alignment with regulatory agencies reduces the risk of delays or rejection and can accelerate approval, ultimately delivering these much-needed therapies to critically ill patient populations.
Biography
Dr. Neethling holds advanced degrees in Transplantation Immunology and completed postdoctoral research at Harvard and Oklahoma State. Before joining Eurofins Discovery in 2021, she spent nearly a decade at Boehringer Ingelheim as a Sr. Principal Scientist, leading antibody discovery for novel biologics across diverse therapeutic areas.
Olivier Mirguet brings over 20 years of drug discovery experience across pharma and CROs. He has co-authored 45+ publications and patents, and contributed to three clinical compounds. In 2023, he joined Eurofins Discovery as Scientific Director for Integrated Drug Discovery within DiscoveryOne.
From DDW Volume 26 – Issue 4, Fall 2025 – Read the digital issue
